Detection of hematogenous micrometastasis in patients with transitional cell carcinoma

被引:39
作者
Güdemann, CJ
Weitz, J
Kienle, P
Lacroix, J
Wiesel, MJ
Soder, M
Benner, A
Staehler, G
Doeberitz, MV
机构
[1] Univ Heidelberg, Chirurg Klin, Sekt Mol Diagnost & Therapie, Div Mol Diagnost & Therapy,Dept Urol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Dept Surg, D-6900 Heidelberg, Germany
[3] German Canc Res Ctr, Cent Unit Biostat, D-6900 Heidelberg, Germany
关键词
circulating tumor cells; reverse transcriptase; polymerase chain reaction; transitional cell carcinoma; metastasis;
D O I
10.1016/S0022-5347(05)67418-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Cytokeratin 20 (CK 20) is selectively expressed in urothelium, gastric intestinal epithelium, in Merkel cells and in a variety of malignant neoplasms. CK 20 RT-PCR assay has been extensively used to detect isolated cancer cells in peripheral blood, lymph nodes and bone marrow samples of patients with colorectal carcinoma. Since CK-20 is also actively expressed in transitional cell carcinoma (TCC), we analyzed, whether CK 20 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is suitable to detect residual tumor cells in patients with transitional cell carcinoma of the bladder and the upper urinary tract. Materials and Methods: Nested Reverse Transcriptase Polymerase Chain Reaction assay was used to analyze CK 20 transcripts in peripheral venous blood samples and tumor biopsies of 49 patients with transitional cell carcinoma. Blood samples of 22 healthy volunteers served as negative controls. Results: CK 20 mRNA was detectable in blood samples of 12 of 49 patients with TCC. All blood samples of the control group tested negative. The detection rate for CK 20 mRNA significantly correlated (p = 0.0019, Cochran-Armitage Trend Test;) to the stage of disease and increased from 0% in stage pTa to 63% in stage pT4. Conclusions: These results suggest that CK 20 is a suitable marker for the detection of disseminated TCC cells in peripheral venous blood samples and may be helpful in the molecular staging of TCC patients. The prognostic relevance has to be evaluated in further followup,
引用
收藏
页码:532 / 536
页数:5
相关论文
共 24 条
  • [1] Agresti A., 1990, Analysis of categorical data
  • [2] BROSSART P, 1995, CANCER RES, V55, P4065
  • [3] Cytokeratin 20: A new marker for early detection of bladder cell carcinoma
    Buchumensky, V
    Klein, A
    Zemer, R
    Kessler, OJ
    Zimlichman, S
    Nissenkorn, I
    [J]. JOURNAL OF UROLOGY, 1998, 160 (06) : 1971 - 1974
  • [4] BURCHILL SA, 1995, BRIT J CANCER, V71, P831
  • [5] Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases
    Ghoneim, MA
    ElMekresh, MM
    ElBaz, MA
    ElAttar, IA
    Ashamallah, A
    [J]. JOURNAL OF UROLOGY, 1997, 158 (02) : 393 - 399
  • [6] Cytokeratin 20 as an objective marker of urothelial dysplasia
    Harnden, P
    Eardley, I
    Joyce, AD
    Southgate, J
    [J]. BRITISH JOURNAL OF UROLOGY, 1996, 78 (06): : 870 - 875
  • [7] Expression of cytokeratin 20 redefines urothelial papillomas of the bladder
    Harnden, P
    Mahmood, N
    Southgate, J
    [J]. LANCET, 1999, 353 (9157) : 974 - 977
  • [8] Henke W, 1997, INT J CANCER, V70, P52
  • [9] Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region
    Holmang, S
    Hedelin, H
    Anderstrom, C
    Johansson, SL
    [J]. JOURNAL OF UROLOGY, 1997, 158 (02) : 389 - 392
  • [10] ISRAELI RS, 1994, CANCER RES, V54, P6306